Rheumatology Advance Access originally published online on December 24, 2008
Rheumatology 2009 48(3):315-316; doi:10.1093/rheumatology/ken456
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
© The Author 2008. Published by Oxford University Press on behalf of the British Society for Rheumatology. All rights reserved. For Permissions, please email: journals.permissions@oxfordjournals.org
LETTERS TO THE EDITOR |
Very low prevalence of anti-CCP antibodies in rheumatoid factor-negative psoriatic polyarthritis
1Rheumatology Section, Department of Clinical Medicine and Immunological Science, Policlinico le Scotte, Siena, Italy
Correspondence to: P. Pasquetti, Rheumatology Section, Department of Clinical Medicine and Immunological Science, Policlinico le Scotte, v.le Bracci 16, 53100, Siena, Italy. E-mail: pasquetti3@virgilio.it
| The first 10% of the full text of this article appears below. |
SIR, PsA is a heterogeneous disease that can develop with several patterns of articular involvement that could vary over time. In clinical practice, the diagnosis is based on assessment of typical signs (dactylitis, enthesitis, DIP joints involvement and inflammatory back pain), although sometimes the broad spectrum of disease expression makes it difficult.
According to Moll and Wright criteria RF should be negative in PsA, even if most recent classification criteria tend to confirm the diagnosis despite RF presence [1].
Antibodies against cyclic citrullinated peptide (anti-CCP) were for